It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Metastatic cancer is associated with poor patient prognosis but its spatiotemporal behavior remains unpredictable at early stage. Here we develop MetaNet, a computational framework that integrates clinical and sequencing data from 32,176 primary and metastatic cancer cases, to assess metastatic risks of primary tumors. MetaNet achieves high accuracy in distinguishing the metastasis from the primary in breast and prostate cancers. From the prediction, we identify Metastasis-Featuring Primary (MFP) tumors, a subset of primary tumors with genomic features enriched in metastasis and demonstrate their higher metastatic risk and shorter disease-free survival. In addition, we identify genomic alterations associated with organ-specific metastases and employ them to stratify patients into various risk groups with propensities toward different metastatic organs. This organotropic stratification method achieves better prognostic value than the standard histological grading system in prostate cancer, especially in the identification of Bone-MFP and Liver-MFP subtypes, with potential in informing organ-specific examinations in follow-ups.
The location and timing of metastasis are still fundamentally unpredictable. Here the authors present the Metastatic Network model, a machine learning framework that integrates clinical data and DNA alterations to predict the risk of metastasis to specific organs as well as clinical outcomes
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 The Hong Kong University of Science and Technology, Department of Chemical and Biological Engineering, Hong Kong SAR, China (GRID:grid.24515.37) (ISNI:0000 0004 1937 1450); Tencent AI Lab, Shenzhen, China (GRID:grid.471330.2) (ISNI:0000 0004 6359 9743)
2 The Hong Kong University of Science and Technology, Department of Chemical and Biological Engineering, Hong Kong SAR, China (GRID:grid.24515.37) (ISNI:0000 0004 1937 1450)
3 The Hong Kong University of Science and Technology, Division of Life Science, Hong Kong SAR, China (GRID:grid.24515.37) (ISNI:0000 0004 1937 1450)
4 The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital, Qingyuan, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072); Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072); The University of Texas MD Anderson Cancer Center, Department of Radiation Oncology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
5 Fudan University Shanghai Cancer Center, Department of Hepatic Surgery, Shanghai, China (GRID:grid.452404.3) (ISNI:0000 0004 1808 0942); Fudan University, Department of Oncology, Shanghai Medical College, Shanghai, China (GRID:grid.8547.e) (ISNI:0000 0001 0125 2443)
6 The Chinese University of Hong Kong, Institute of Digestive Disease, Hong Kong SAR, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482); The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong SAR, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482); The Chinese University of Hong Kong, State Key Laboratory of Digestive Disease, Hong Kong SAR, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482); The Chinese University of Hong Kong, Li Ka Shing Institute of Health Sciences, Hong Kong SAR, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482); CUHK Shenzhen Research Institute, Shenzhen, China (GRID:grid.464255.4)
7 Capital Medical University, Department of Neurosurgery, Beijing Tiantan Hospital, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X)
8 The Hong Kong University of Science and Technology, Department of Chemical and Biological Engineering, Hong Kong SAR, China (GRID:grid.24515.37) (ISNI:0000 0004 1937 1450); The Hong Kong University of Science and Technology, Division of Life Science, Hong Kong SAR, China (GRID:grid.24515.37) (ISNI:0000 0004 1937 1450); The Hong Kong University of Science and Technology, State Key Laboratory of Molecular Neuroscience, Hong Kong SAR, China (GRID:grid.24515.37) (ISNI:0000 0004 1937 1450); Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong SAR, China (GRID:grid.24515.37) (ISNI:0000 0004 1937 1450)